• Add this page to "Favorite pages"
  • Print Text
Here begins the text.

Safety Information announced by MHLW

Date Title
June 20, 2013 Revision of the Precautions section of the package inserts of Recombinant Adsorbed Bivalent Human Papillomavirus-like Particle Vaccine (derived from Trichoplusia ni cells) and Recombinant Adsorbed Quadrivalent Human Papillomavirus Virus-Like Particle Vaccine (Yeast Origin)

Related information:
Main information on the safety review meeting on Cervarix and GARDASIL
February 14, 2012 PFSB/SD Notification 0214-9 "Call attention to the Precautions of anti-influenza virus drugs"
June. 23, 2011 Safety Measures for diabetes medication "pioglitazone-containing products"

Annex
March. 29, 2011 < Q and A >
Resuming vaccination with the pediatric pneumococcal conjugate vaccine and the Hib vaccine (Issued by the Tuberculosis and Infectious Disease Control Division, Health Service Bureau and Safety Division, Pharmaceutical and Food safety Bureau)

For Japanese: http://www.mhlw.go.jp/stf/houdou/2r98520000016yw1.html

[Reference]
Safety review results pneumococcal conjugate vaccine and Haemophilus influenza type b (Hib) vaccine foe pediatrics (Issued as on March 24th by the Joint meeting of subcommittee on Drug Safety and Vaccine Adverse Reaction Review Committee for Carcinoma of the Uterine Cervix)

For Japanese: http://www.mhlw.go.jp/stf/houdou/2r985200000167mx.html

(List of Fatal Case Reports)

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000028957
0
Safety Information announced by MHLW
/english/safety/info-services/drugs/mhlw-released/0001.html
en